Key result
Immune checkpoint inhibitors linked to higher major cardiovascular events in cancer patients versus non-exposed controls.
Why the study?
The true incidence of major adverse cardiovascular events other than myocarditis after ICI treatment remains unknown because late-occurring side effects are rarely reported in prospective trials.
Does immune checkpoint inhibitor treatment increase the incidence of MACE in cancer patients compared to non-ICI treated cancer patients and population controls?
Cohort (n=672)
Does immune checkpoint inhibitor treatment increase the incidence of MACE in cancer patients compared to non-ICI treated cancer patients and population controls?
Immune checkpoint inhibitors are associated with a significantly higher incidence of major adverse cardiovascular events, particularly heart failure, compared to matched cancer and population controls.
Answers are grounded in this paper and cite their sources.
MACE incidence appears elevated after ICI exposure in real-world data; supports targeted surveillance in those with prior HF but leaves causal risk open.
PURPOSE: In rare cases, immune checkpoint inhibitors (ICIs) cause immune-mediated myocarditis. However, true incidence of other major adverse cardiovascular events (MACEs) after ICI treatment remains unknown, mainly because late occurring side effects are rarely reported in prospective clinical trials. The aims of this study were (1) to identify incidence and risk factors of MACE in a real-life ICI-treated cancer cohort and (2) to compare incidence rates with patients with cancer who are not treated with ICIs and population controls. METHODS: In total, 672 patients treated with ICIs were included. The primary end point was MACE, a composite of acute coronary syndrome, heart failure (HF), stroke, and transient ischemic attack. Secondary outcomes were acute coronary syndrome and HF separately. Incidence rates were compared between groups after matching according to age, sex, cardiovascular history, and cancer type. Cumulative incidence rates were significantly higher in the ICI group compared with the cancer cohort not exposed to ICI and the population controls, mainly driven by a higher risk of HF events. CONCLUSION: Cardiovascular events during and after ICI treatment are more common than currently appreciated. Patients at risk are those with a history of cardiovascular disease. Compared with matched cancer and population controls, MACE incidence rates are significantly higher, suggesting a potential harmful effect of ICI treatment besides the underlying risk.
No takes yet. Share an insight, caveat, or question.
Laenens et al. (2022) conducted a cohort in Cancer (n=672). Immune checkpoint inhibitors (ICIs) vs. Cancer patients not treated with ICIs and population controls was evaluated on MACE (composite of acute coronary syndrome, heart failure, stroke, and transient ischemic attack) (p=0.041). Immune checkpoint inhibitor treatment in cancer patients was associated with a higher cumulative incidence of major cardiovascular events compared to non-exposed controls.
Synapse has enriched 10 related papers. Consider them for comparative context: